These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2007 related items for PubMed ID: 17579866

  • 1. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 2. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.
    Cancer Res; 2009 Jun 01; 69(11):4750-9. PubMed ID: 19458065
    [Abstract] [Full Text] [Related]

  • 3. Analysis of hypoxia-inducible factor-1alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry.
    Schwock J, Geddie WR, Hedley DW.
    Cytometry A; 2005 Dec 01; 68(2):59-70. PubMed ID: 16228978
    [Abstract] [Full Text] [Related]

  • 4. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 5. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2004 Dec 01; 10(23):8077-84. PubMed ID: 15585643
    [Abstract] [Full Text] [Related]

  • 6. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 7. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 18; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 8. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.
    Cell Biol Int; 2012 Oct 01; 36(10):893-9. PubMed ID: 22694478
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 10. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb 15; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 11. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
    Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M.
    Anticancer Drugs; 2007 Nov 15; 18(10):1173-81. PubMed ID: 17893518
    [Abstract] [Full Text] [Related]

  • 12. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 13. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 14; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 15. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    Proteomics; 2007 Aug 14; 7(15):2603-16. PubMed ID: 17610208
    [Abstract] [Full Text] [Related]

  • 16. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct 14; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 17. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
    Gossett DR, Bradley MS, Jin X, Lin J.
    Gynecol Oncol; 2005 Feb 14; 96(2):381-8. PubMed ID: 15661225
    [Abstract] [Full Text] [Related]

  • 18. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.
    Williams CR, Tabios R, Linehan WM, Neckers L.
    J Urol; 2007 Oct 14; 178(4 Pt 1):1528-32. PubMed ID: 17707057
    [Abstract] [Full Text] [Related]

  • 19. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
    Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, Shao Y, Zagzag D.
    Anticancer Drugs; 2007 Sep 14; 18(8):875-82. PubMed ID: 17667592
    [Abstract] [Full Text] [Related]

  • 20. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 14; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 101.